Trial · NCT02737501
Participant flow21
How many started, completed or left each group, period by period.
1 to 20 of 21
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Randomized Phase | STARTED | Randomized Phase: Brigatinib 90 mg QD/180 QD | 137 | |
| Randomized Phase | STARTED | Randomized Phase: Crizotinib 250 mg BID | 138 | |
| Randomized Phase | STARTED | Crossover Phase: Brigatinib 90 mg QD/180 mg QD | 0 | |
| Randomized Phase | Safety Analysis Set | Randomized Phase: Brigatinib 90 mg QD/180 QD | 136 | |
| Randomized Phase | Safety Analysis Set | Randomized Phase: Crizotinib 250 mg BID | 137 | |
| Randomized Phase | Safety Analysis Set | Crossover Phase: Brigatinib 90 mg QD/180 mg QD | 0 | |
| Randomized Phase | COMPLETED | Randomized Phase: Brigatinib 90 mg QD/180 QD | 20 | |
| Randomized Phase | COMPLETED | Randomized Phase: Crizotinib 250 mg BID | 84 | |
| Randomized Phase | COMPLETED | Crossover Phase: Brigatinib 90 mg QD/180 mg QD | 0 | |
| Randomized Phase | NOT COMPLETED | Randomized Phase: Brigatinib 90 mg QD/180 QD | 117 | |
| Randomized Phase | NOT COMPLETED | Randomized Phase: Crizotinib 250 mg BID | 54 | |
| Randomized Phase | NOT COMPLETED | Crossover Phase: Brigatinib 90 mg QD/180 mg QD | 0 | |
| Crossover Phase | STARTED | Randomized Phase: Brigatinib 90 mg QD/180 QD | 0 | |
| Crossover Phase | STARTED | Randomized Phase: Crizotinib 250 mg BID | 0 | |
| Crossover Phase | STARTED | Crossover Phase: Brigatinib 90 mg QD/180 mg QD | 65 | |
| Crossover Phase | COMPLETED | Randomized Phase: Brigatinib 90 mg QD/180 QD | 0 | |
| Crossover Phase | COMPLETED | Randomized Phase: Crizotinib 250 mg BID | 0 | |
| Crossover Phase | COMPLETED | Crossover Phase: Brigatinib 90 mg QD/180 mg QD | 10 | |
| Crossover Phase | NOT COMPLETED | Randomized Phase: Brigatinib 90 mg QD/180 QD | 0 | |
| Crossover Phase | NOT COMPLETED | Randomized Phase: Crizotinib 250 mg BID | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02737501/flow